Hanmi/Aptose’s AML Contender Shows Early Promise
Oral Myeloid Kinome Inhibitor Set For Expansion Trials
Executive Summary
Hanmi Pharmaceutical’s hopes for AML drug candidate HM43239, licensed out to Aptose Biosciences, are rising amid accumulating clinical data that appear to put the oral myeloid kinome inhibitor on the right track to registrational studies.